ArticleRespiratory research2026
Effect of COVID-19 vaccination and SARS-CoV-2 infection status on mortality risk in patients with chronic obstructive pulmonary disease: a nationwide population-based cohort study.
Article in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Inflammatory bowel disease and risk of non-tuberculous mycobacterial pulmonary disease: a nationwide retrospective cohort study in Korea.Journal of thoracic disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundThe coronavirus disease 2019 (COVID-19) vaccination is suggested to be effective in improving outcomes of chronic obstructive pulmonary disease (COPD). However, real-world evidence on long-term mortality among individuals with COPD, accounting for both vaccination and COVID-19 infection status, remains sparse.
methodsA retrospective cohort study was conducted using datasets from the Korean National Health Insurance system. Through two-step propensity score matching, 716 individuals with COPD were included in the analysis and classified into four groups according to COVID-19 vaccination and severe acute respiratory syndrome coronavirus 2 infection status: 125 COVID-19 vaccinated/uninfected, 125 vaccinated/infected, 233 unvaccinated/uninfected, and 233 unvaccinated/infected. A multivariable Cox proportional hazards regression analysis was conducted to assess the risk of mortality following COVID-19 vaccination and SARS-CoV-2 infection status.
resultsThe median follow-up period was 420 days, during which 79.6% of study participants completed follow-up. Mortality rates were lowest in the vaccinated/uninfected individuals (281/10,000 person-years), followed by the vaccinated/infected individuals (661/10,000 person-years) and unvaccinated/uninfected individuals (2,106/10,000 person-years) and highest in unvaccinated/infected individuals (4,510/10,000 person-years). Compared with vaccinated/uninfected individuals, unvaccinated/infected individuals had a significantly higher annual risk of mortality (adjusted hazard ratio [aHR] = 13.51, 95% confidence interval [CI] = 4.91–37.13). The annual mortality risk was also significantly higher among unvaccinated/uninfected individuals (aHR = 6.01, 95% CI = 2.15–16.81). On the other hand, vaccinated/infected individuals (aHR = 2.32, 95% CI = 0.71–7.55) did not exhibit a significantly increased annual mortality risk compared with vaccinated/uninfected individuals.
conclusionCOVID-19 vaccination is associated with reduced long-term COPD-related mortality, whereas mortality risk was higher in unvaccinated/uninfected individuals than in vaccinated/infected individuals. Vaccination-related factors may confer broader benefits on COPD outcomes beyond direct protection against COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.